Health Technology

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Retrieved on: 
Saturday, April 6, 2024
Health Technology, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Practice Management, Apps, Applications, Managed Care, General Health, Hospitals, Artificial Intelligence, Other Technology, Software, Networks, Health, Mobile, Wireless, Intelligence, Workspace, Medicine, HLA, Research, Genotype, Prevalence, AI

Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.
  • Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation.
  • This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.
  • Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes.

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

Retrieved on: 
Saturday, April 6, 2024
Research, Technology, Medical Devices, Health Technology, Cardiology, Software, Health, Data Management, Science, Artificial Intelligence, Aortic stenosis, Aortic regurgitation, Patient, Mortality, MD, American College, TAVR, Multimedia, Teaching

egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).

Key Points: 
  • egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).
  • This press release features multimedia.
  • “This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor distinct characteristics in this population.
  • Recent conservative estimates suggest that over 500,000 patients in the United States are diagnosed with moderate or severe AR, indicating a substantial opportunity for novel therapeutic options to treat patients suffering from AR.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

Maximus Declares Quarterly Cash Dividend of $0.30 per Share

Retrieved on: 
Friday, April 5, 2024
Technology, Managed Care, General Health, Hospitals, Payments, Health, Health Technology, Health Insurance, Other Technology, Telemedicine, Virtual Medicine, Software, Other Health, Networks, Internet, Mobile, Wireless, Data Management, Practice Management, MMS

Maximus (NYSE: MMS), a leading provider of government services worldwide, announced today that its Board of Directors has approved a quarterly cash dividend of $0.30 per share, payable on May 31, 2024, to shareholders of record on May 15, 2024.

Key Points: 

Maximus (NYSE: MMS), a leading provider of government services worldwide, announced today that its Board of Directors has approved a quarterly cash dividend of $0.30 per share, payable on May 31, 2024, to shareholders of record on May 15, 2024.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan

Retrieved on: 
Friday, April 5, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Clinical Trials, Immune system, Human, Notifiable disease, Therapy, Muscle atrophy, Multimedia, Metabolism, Sarcopenia, Facial muscles, DSM-IV codes, Cell, Inc., Vaccine

View the full release here: https://www.businesswire.com/news/home/20240405602477/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405602477/en/
    “Aging is a manifestation of immune decline.
  • This staggering statistic emphasizes the need for interventions that restore immune function to prevent the onset of such diseases.
  • By focusing on the prevention of immune dysregulation and the maintenance of immune health, Immunis aims to empower individuals to take charge of how they age.
  • Immunis aims to ignite a conversation on the profound benefits of nurturing the immune system for a transformative impact on muscle health and ultimately, human healthspan.

Tidepool Achieves SOC 2 Type II Compliance

Retrieved on: 
Friday, April 5, 2024
Software, Health, Diabetes, Data Management, Health Technology, Technology, Other Technology, Security, Single sign-on, SOC, AICPA, CSA, Attention, Risk management, PHI, GDPR, CCPA, NIST, HIPAA, American Institute, SAAS, PCI, SSO, EHR, SOC 2, ISO, Data management, Certified Public Accountant, Audit

Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the achievement of SOC 2 Type II compliance in accordance with American Institute of Certified Public Accountants (AICPA) standards for SOC for Service Organizations also known as SSAE 18.

Key Points: 
  • Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the achievement of SOC 2 Type II compliance in accordance with American Institute of Certified Public Accountants (AICPA) standards for SOC for Service Organizations also known as SSAE 18.
  • Achieving this standard with an unqualified opinion serves as third-party industry validation that Tidepool provides enterprise-level security for customers’ data secured in the Tidepool Data Platform.
  • “With this attestation, we are confirming our ongoing commitment to the compliance standards reflected in achieving and maintaining SOC 2 Type II compliance,” says Ben Derr, Lead Security Engineer at Tidepool.
  • An unqualified opinion on an SOC 2 Type II audit report demonstrates to Tidepool’s current and future customers that they manage their data with the highest standard of security and compliance.

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Artificial Intelligence, Genetics, Science, Diagnosis, Lung cancer, Algorithm, Immunotherapy, Patient, 2.0, University of Queensland, Biomarker, Tumor microenvironment, Marie Cassidy, Cancer, University, AI, Doctor of Philosophy, Medicine, AACR, Neoplasm, Drug development, Pathology, Therapy, Translational medicine, H&E, Medical imaging

Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.

Key Points: 
  • Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.
  • Leveraging Nucleai's unique AI spatial biology solution, the research uncovered the correlation between the metabolic state and spatial distribution of tumor and immune cells in the tumor microenvironment, shedding new light on treatment outcomes and potential resistance mechanisms.
  • Nucleai is driving innovation in cancer research and collaborating with leading scientists to translate these findings into tangible benefits for patients and healthcare providers worldwide.
  • By integrating spatial biology with AI, Nucleai creates actionable insights from complex pathology data, setting a new standard for diagnosis and treatment, and advancing precision medicine.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
Friday, April 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.